ThromboGenics®

Advancing Science. Enhancing Vision.®

ANNUAL REPORT 2012

CONTENT

Contents

Key figures 2012

Net results

Net results
2009: €-14,070,000
2010: €-13,942,000
2011: €-21,637,000

2012:
€+30,415,000

181 employees*



Employees
2009: 58
2010: 76
2011: 96
2012: 181

(*) including third party partners

3 locations

500 000 eligible patients for JETREA®*

EUROPE
250,000-300,000

USA
250,000



(*) ThromboGenics and Alcon internal estimates

Interview with the CEO & Chairman

Prof. Dr. Désiré Collen, Chairman Dr. Patrik De Haes, CEO

What was the Company's most important achievement in 2012?

PDH: Gaining approval for JETREA® for the treatment of symptomatic vitreomacular adhesion (VMA) from the US FDA was undoubtedly the most important achievement for ThromboGenics in 2012; October 17, 2012 will always be regarded a major milestone in the Company's history. Developing new drugs is difficult and risky, so for ThromboGenics to achieve this major milestone, when so many companies have failed, reflects very positively on our whole organization.

DC: The potential for JETREA® to change the treatment paradigm for retinal disease, and the quality of our regulatory submission was evident at the FDA Advisory Meeting in July, with the committee voting 10-0 to support the approval of this innovative new product. JETREA® is first pharmacological treatment for symptomatic VMA, which up until now could only be treated surgically.

Since January 14, JETREA® has been available in the US and all of us at ThromboGenics are very excited to hear about patients who have regained their visual capabilities thanks to JETREA®. These positive patient outcomes are the main reason why we are developing new products and are a key driver behind our success.

DC: Next to the October 2012 FDA approval of JETREA® for the treatment of symptomatic vitreomacular adhesion (VMA), the team recently also landed EMA approval for JETREA® for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. We launched JETREA® in the US around mid January of 2013.

The recent EMA approval paved the way for launching JETREA® in Europe as well.

Successfully working with two regulatory agencies in parallel has demonstrated the great commitment of the entire ThromboGenics team.

Why did you decide that Alcon was the best partner to commercialize JETREA® outside the US?

PDH: The deal with Alcon was another key milestone for ThromboGenics in 2012. We decided that Alcon was the best partner for a number of reasons. The first was that we would retain the rights to JETREA® in the US. This was critical to ThromboGenics' strategy of building its own ophthalmology franchise and generating significant shareholder value. The second was that Alcon as the global leader in eyecare has the market reach outside the US to ensure that JETREA® could reach the many patients that we believe could benefit from this innovative pharmaceutical product for the treatment of symptomatic VMA. The third strategic reason is that Alcon viewed the deal very much as a strategic partnership. This is reflected in the way we are working together not only on the commercialization of JETREA® in Europe but also on the further development of our new product.

DC: The deal with Alcon also made sense financially, giving us both attractive short term returns in upfront and near-term milestones payments but also over the medium and longer term via the significant level of royalties we will receive on Alcon's sales of JETREA®.

Can you outline how the ThromboGenics organization has developed in 2012?

PDH: The key changes to the ThromboGenics organization have been driven by our preparations for the recent launch of JETREA® in the US. As a result we have put considerable effort and investment in building our commercial infrastructure in the US, particularly following the product's approval by the FDA. We now have a strong commercial team in place including approximately 30 sales representatives, and 15 reimbursement specialists, supported by other important functions such as marketing and medical affairs. The ability to put such a strong organization in place has been helped considerably by our relationship with Quintiles.

→

DC: The build-up of our commercial organization has taken place at a time when we have continued to invest in our research and development activities. JETREA® was the result of our own research and we believe that research success is critical to ThromboGenics achieving its goal of becoming a successful global ophthalmology company.

What are your main goals for 2013?

PDH: The big priority for the Company is to commercialize JETREA® successfully, both in the US and Europe.

We want to make sure that US sales of JETREA® continue to grow. There is already a high level of awareness of JETREA® amongst the US retina community and our commercial organization is now focused on turning this into usage and sales. In parallel we are working to ensure that the reimbursement of JETREA® is as simple and straightforward as possible. Our aim is to make sure that all US residents have access to JETREA®, a novel eye medicine that we believe will significantly change the way symptomatic VMA is treated.

DC: Outside the US, we are working closely with Alcon on market access and gaining reimbursement for JETREA® in the first markets where it will be launched, starting with Germany and the UK.

Elsewhere we are supporting Alcon to gain the approvals needed to market the product as well securing reimbursement.

What can the Company's key stakeholders expect in 2013?

DC: While delivering on our commercial objectives in the US and Europe, we will need to ensure that we manage the expectations of our various stakeholders. We have a track-record of delivering on our commitments, and we intend to continue to do so in the commercial domain. With ThromboGenics and JETREA® enjoying a good reputation in a growing global ophthalmology market, we believe we are in good shape to deliver value to all of our stakeholders while improving the treatment options for patients with symptomatic VMA.

We look forward to another year filled with first commercial successes and great shareholder returns.

How do you intend on becoming a leading ophthalmology company?

PDH: First of all, we want JETREA® to become a great success in all markets where it is launched, either by ThromboGenics or Alcon. This is clearly our number one priority and will be the major focus of all of the members of the ThromboGenics team involved in the commercialization of JETREA®.

Given that JETREA® is the first pharmacological treatment for a disease that would typically be treated by surgery, we believe that we have the ideal product to start building our ophthalmology franchise. This optimism has been reinforced by listening to the positive, first experiences of treating retina specialists and, even more important, of their patients who have seen a rapid improvement in their vision.

For 2013, we will continue our efforts to support medical education and generate greater awareness of and understanding about symptomatic vitreomacular adhesion or vitreomacular traction, as an important unmet medical need. You can also expect more podium presentations about JETREA® in 2013.

Dr. Patrik De Haes
CEO

Prof. Dr. Désiré Collen
Chairman

ThromboGenics in brief

ThromboGenics is an integrated biopharmaceutical Company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company's lead product, JETREA® (ocriplasmin), was launched in the US on January 14, 2013 through the Company's own commercial organization. JETREA® was granted approval by the US FDA for the treatment of symptomatic VMA in October 2012 and is the first drug to be approved for this important indication.

ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of JETREA® outside the United States in March 2012. Alcon is the global leader in eye care.

Under the terms of the agreement, ThromboGenics has already received €75 million in upfront and milestone payments. It is eligible to receive up to a total of €375 million. In addition, the Company will receive significant royalties from Alcon's net sales of JETREA® outside the US.

A further important part of this strategic alliance is that ThromboGenics and Alcon will share the costs equally of developing JETREA® for a number of new vitreoretinal indications.

ThromboGenics HQ Leuven, Belgium

On March 15, 2013, the European Commission approved JETREA® in the European Union for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. VMT, which in the US is referred to as symptomatic VMA, is an age-related progressive, sight-threatening condition that may lead to visual distortion, decreased visual acuity and central blindness as a result of a macular hole. The approval and launch of JETREA® in Europe triggers a €90 million payment to ThromboGenics, €45 million for approval and €45 million for first sale of the product.

ThromboGenics is also exploring anti-PlGF (Placental Growth Factor), formerly referred to as TB-403, for the treatment of ophthalmic and oncology indications.

ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR.

Mission

ThromboGenics is dedicated to developing and commercializing new pharmacologic treatments that address important unmet clinical needs in ophthalmology and oncology.

By delivering on this goal ThromboGenics intends to assist clinicians around the world to continually improve treatment for patients with sight-threatening ophthalmic disorders and cancer.

As part of its corporate evolution, ThromboGenics has been building a team consisting of scientists, sales and marketing experts with deep commercial ophthalmic and retina experience. Investing in this capability is designed to generate the best returns for our shareholders and to place the Company in a strong position to achieve its goal of becoming a major global ophthalmic player.

Central to ThromboGenics achieving its corporate goals is pioneering research and development, which has played a crucial role in ThromboGenics' success to-date. Today, the Company has highly qualified research personnel focused on developing new treatments for both ophthalmic and cancer indications.


PROTEOLYTIC ENZYME
THROMBOGENICS
ANTI-PIGF
INNOVATIVE
MEDICINE
NOVEL TREATMENT
SYMPTOMATIC
R&D
JETREA®
ONCOLOGY
RETINA
MACULAR HOLE
BIOPHARMACEUTICAL COMPANY
COMMERCIALIZATION
SYMPTOMATIC VITREOMACULAR ADHESION
SYMPTOMATIC VMA
AMBITION
OPHTHALMOLOGY
TB-403
AMD
OPHTHALMIC MEDICINE
VMT
OCRIPLASMIN

Corporate objectives and strategy

Becoming a leading global ophthalmology company

ThromboGenics is well positioned to become a leading global ophthalmology company developing and commercializing innovative therapies for significant eye diseases with a high unmet medical need.

Successfully commercializing JETREA® in the US via our own commercial organization

The recent US launch of JETREA® was a major corporate milestone for ThromboGenics. The Company's 84 person commercial organization (employees and third party partners) is now focused on building the sales of this innovative new product for the treatment of symptomatic VMA. ThromboGenics is confident that JETREA® will enjoy significant success in the US given the benefits it delivers and the already high awareness the product enjoys with the retina community.

Educational materials JETREA®

Supporting Alcon to successfully commercialize JETREA® outside the US

The approval of JETREA® in Europe paves the way for Alcon to launch the product initially in markets such as Germany and the UK. ThromboGenics is currently working with Alcon on market access and reimbursement activities in the major European pharmaceutical markets. The initial launches of JETREA® in Europe will mark the start of Alcon bringing JETREA® to patients around the world who could benefit from the first pharmacological treatment for symptomatic VMA.

Working with Alcon to extend the clinical utility of JETREA®

A key element of ThromboGenics' strategic alliance with Alcon relates to the future development of JETREA®.

The companies are working on a plan that will cover the development of new formulations of the product as well as clinical trials for a number of new indications. The investment needed to develop the use of JETREA® will be shared equally with Alcon.

Raising awareness of VMA

ThromboGenics, in conjunction with Alcon, is continuing to support medical education efforts to increase the awareness of symptomatic VMA as an important unmet medical need.

Building a broader global ophthalmology franchise

ThromboGenics is already building its presence in ophthalmology beyond JETREA®. To achieve this, the Company needs to access new novel ophthalmic medicines that will help expand its ophthalmology franchise. The Company intends to source these products from its own research, via joint development/licensing deals or possibly acquisitions.

Dr. Baruch D. Kuppermann, MD, PhD

Corporate highlights 2012

(including post-period events)

March 18, 2013
ThromboGenics starts trading as part of the BEL20 Index.

March 15, 2013
ThromboGenics' JETREA® granted EU approval for vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.

January 18, 2013
ThromboGenics receives a positive CHMP (Committee for Medicinal Products for Human Use) opinion for JETREA® for vitreomacular traction (VMT) including when associated with macular hole of diameter less than or equal to 400 microns, paving the way for the product's potential EU approval.

January 14, 2013
ThromboGenics launches JETREA® (ocriplasmin) in the US for the treatment of symptomatic vitreomacular adhesion (VMA).

Dr. Jennifer Lim administering JETREA®

Licensing Deal of the Year Award – Scrip Awards 2012

November 28, 2012
ThromboGenics wins the Licensing Deal of the Year Award at the Scrip Awards 2012 in London for its commercial partnership agreement with Alcon (Novartis).

November 27, 2012
JETREA® is selected for Single Technology Appraisal (STA) by the UK's National Institute for Health and Clinical Excellence (NICE).

October 18, 2012
The US FDA approves ThromboGenics' JETREA® (ocriplasmin) as the first pharmacological agent for the treatment of symptomatic VMA.

The New England Journal of Medicine Paper

August 15, 2012
ThromboGenics announces the publication of the New England Journal of Medicine Paper Entitled 'Enzymatic Vitreolysis with Ocriplasmin for Vitreomacular Traction and Macular Hole'.

July 27, 2012
The FDA Advisory Committee recommends ocriplasmin for the treatment of symptomatic VMA.

July 3, 2012
ThromboGenics announces that the FDA accepts the filing and grants priority review to its biologics license application for ocriplasmin intravitreal injection.

March 29, 2012
ThromboGenics completes a private placement, raising €77.8 million via the issue of 3,244,675 new shares.

March 16, 2012
ThromboGenics enters into an agreement with Alcon (Novartis) to commercialize JETREA® outside the US. Under the terms of the agreement ThromboGenics could receive €375 million in upfront and milestone payments plus significant royalties on Alcon's sales of JETREA®.

March 5, 2012
ThromboGenics opens its new US offices in Iselin, New Jersey.

ThromboGenics US offices, 6th floor

INTRODUCTION

Outlook for 2013

ThromboGenics enters 2013 well placed to achieve JETREA®'s global commercial potential. This follows JETREA®'s successful launch in the US and the EU approval that paves the way for its launch in Europe.

In the US, where ThromboGenics is commercializing JETREA® by itself, the Company is committed to ensuring that the product is made available to US patients and physicians as quickly as possible while maintaining the highest quality standards.

The Company's specialized US commercial team, including its salesforce, is focused on converting the already high awareness of JETREA® into product revenues. It will initially target the 2,100 retinal physicians in the US who treat most of the patients presenting with symptomatic VMA.

The Centers for Medicare and Medicaid Services (CMS) has recently granted JETREA® a unique billing code for use in the Hospital outpatient setting, C9298, that will become effective April 1, 2013. ThromboGenics has applied for a permanent J-code which it expects to receive and take effect on January 1, 2014. A permanent J-code would lead to the reimbursement process for JETREA® being automated.

The European approval will allow Alcon, ThromboGenics' strategic commercial partner for JETREA® outside the US, to launch this novel product in the EU. JETREA® will be launched in Germany and the UK before being rolled out in other countries in Europe and beyond.

ThromboGenics is playing a strategic role in the commercialization and reimbursement of the drug in the biggest five markets in the EU. Its market access team, alongside Alcon, is negotiating with payers in the main European markets to ensure the drug is reimbursed appropriately.

The European approval and launch of JETREA® will together trigger a total of €90 million in milestone payments to ThromboGenics from Alcon, as part of the March 2012 commercialization agreement. This agreement also entitles ThromboGenics to receive significant royalties on Alcon's sales of JETREA® outside the US.

In 2013, ThromboGenics along with its partner Alcon, expect to announce their plans to expand the JETREA® franchise. The plans are expected to include enhanced formulations of the drug as well evaluating its use in other back-of-the-eye diseases where adhesion is thought to play an important role.

2013 promises to be an important and exciting year for ThromboGenics as the Company works towards its goal of becoming a growing, profitable integrated biopharmaceutical company focused on bringing innovative ophthalmic and oncology medicines to market.

JETREA® (ocriplasmin)

On October 18, 2012 the US FDA approved JETREA® (ocriplasmin) for the treatment of symptomatic VMA. On March 15, 2013, the European Commission approved JETREA® for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. This is the first time that a drug has been approved for the treatment of this important vitreoretinal disease, which previously could only be treated with surgery once the patient's condition had deteriorated.

Symptomatic VMA

ThromboGenics' extensive clinical development program has shown that JETREA® (ocriplasmin) could play an important role in the treatment of symptomatic VMA. If left untreated, this progressive eye disease generally leads to significant visual distortion, deterioration in visual acuity, and in some cases central blindness.

The vitreous (the central gel part of the eye) separates from the retina as a consequence of the normal aging process. If the separation is incomplete, generally because of a partial, abnormally strong adhesion, the vitreous will pull on the retina and create traction. This process, which may result in distorted vision or decreased visual acuity, is known as symptomatic VMA.

Market opportunity

Market research has indicated that more than 500,000 patients in the US and the five biggest markets in Europe could be eligible for treatment with JETREA® at launch in both territories.



Protein bonds in vitreomacular interface responsible for VMA

Ocriplasmin breaks protein bonds to resolve VMA



OCT showing symptomatic VMA/VMT

The introduction of optical coherence tomography (OCT), a non-invasive imaging technique that can deliver instant real-time high-resolution images of eye tissue, is expected to an important factor in helping with the uptake of JETREA®.

This is because OCT is leading to better diagnosis of patients with symptomatic VMA and macular hole. As a result the role of VMA in the progression of eye disease is gaining wider recognition among the retinal community.

Nearly every ophthalmologist in the US now has access to OCT and this has led to a better understanding of the role of symptomatic VMA in visual impairment in recent years.

A specific disease code (ICD-9-CM) recognizing VMA has been added in October 2011 to make it easier to gain reimbursement for JETREA® (ocriplasmin) from US healthcare payers. In Europe, ThromboGenics and Alcon are currently working with healthcare authorities in the key markets to demonstrate JETREA®'s value proposition so that it is appropriately reimbursed once it becomes available.

Mechanism of action

Vitrectomy, the surgical separation of the vitreous from the retina has been the only possible treatment option for patients with symptomatic VMA. The procedure holds several risks and may lead to complications such as bleeding, pain, post-operative inflammation or irritation, etc. As a result it is usually only undertaken when the patient's vision has deteriorated significantly.

JETREA® offers for the first time a novel pharmacological option for treating symptomatic VMA in the US and VMT, including when associated with macular hole of diameter less than or equal to 400 microns in Europe. JETREA® has a unique mechanism of action. It is administered as an intravitreal injection. This technique has become routine practice among retina physicians over recent years, and is easy to administer as an outpatient procedure in a doctor's office. It is believed that JETREA® enables the liquefication of the vitreous and its subsequent separation from the retina. If treatment with JETREA® is successful, there is no chance of the symptomatic VMA recurring.

The availability of JETREA® is expected to enable many patients with symptomatic VMA being treated much earlier than the current situation. Successful treatment with JETREA® can lead to improvements in patients' vision and their ability to carry out normal daily living activities.

JETREA®, a biopharma success story

Brief history

1998 (Dec)	D. Collen founds ThromboGene Ltd (later ThromboGenics Ltd) in Ireland for R&D of cardiovascular/oncology / ophthalmology programs in-licensed from KULeuven/VIB. Financed primarily with t-PA royalty rights (71 million Euro over the next 7 years).
1998-on	Research on treatment of ischemic stroke by N. Nagai and D. Collen in CMVB / KULeuven leading to the concept of recombinant microplasmin.
2000	Production of microplasmin for stroke treatment by Y. Laroche and D. Collen in CMVB / KULeuven in collaboration with Thromb-X / ThromboGenics Ltd.
2001-on	Preclinical development of microplasmin for PVD (posterior vitreous detachment) in collaboration with M. de Smet, A. Gandorfer, J.M. Stassen, M. Trese, G. Williams and NuVue.
2004-on	Clinical development of ocriplasmin for symptomatic VMA (vitreomacular adhesion) IIb, directed by S. Pakola.
2006 (Jul)	IPO of ThromboGenics NV on Euronext Brussels (35 million Euro raised).
2006 (Aug)	C. Buyse joins ThromboGenics as CFO. In the following years the Company will raise 204 million euro through four successive private placements to enable the further development of microplasmin / ocriplasmin / JETREA® among other projects.
2007 (Feb)	P. De Haes joins as COO.
2008-on	Following successful completion of the Phase II MIVI trials, the MIVI-trust pivotal Phase III trials are carried out both in the US and in Europe.
2008 (Aug)	At the request of D. Collen, P. De Haes succeeds him as CEO for the day to day management of ThromboGenics NV.
2011	The MIVI-Trust Phase III program is completed successfully and published in the New England Journal of Medicine in August 2012.
2012	The company obtains pre-marketing approval for JETREA® by the FDA in the USA, where it will be marketed by ThromboGenics, Inc. For marketing in the rest of the world, JETREA® is out-licensed to Alcon / Novartis.
2013	ThromboGenics NV enters the Bel 20 index.

Academic origins

The successful development of JETREA®, a first-in-class medicine for the treatment of symptomatic vitreomacular adhesion (VMA), by a Belgian start-up biopharmaceutical Company, from an initial laboratory concept to an approved biopharmaceutical product forms the pinnacle of the career in academic, translational and clinical research and development of Désiré Collen, Founder, former CEO and Chairman of ThromboGenics NV.

This development was only possible with major initial financing by the founder via his t-PA royalties, productive arms' length collaborations with KULeuven and VIB, pragmatic adaptation and reorientation of ThromboGenics' translational research, and a stimulating business environment created by the regional government.

These major achievements required the concerted efforts of a multidisciplinary Executive Committee of senior collaborators (see p. 23)

A truly innovative product

ThromboGenics has completed two pivotal Phase III trials with ocriplasmin for symptomatic VMA including macular hole. Based on these clinical data JETREA® is the first and currently the only drug approved for the treatment of symptomatic VMA. Recent market research conducted by ThromboGenics shows that there are no similar products under regulatory review or in clinical development for this indication. As a result, ThromboGenics believes that JETREA® could represent a significant commercial opportunity given its potential clinical benefits and the size of the patient population it is targeting.

Developments for the future – ophthalmology

ThromboGenics is currently evaluating ocriplasmin in age-related eye diseases and is considering future trials in diabetic retinopathy.

Manufacturing process JETREA®

Our staff

ThromboGenics employees come from a wide variety of backgrounds. Despite working in different positions, everyone at the Company is striving towards the same goal: making ThromboGenics a global leader in providing cutting-edge medicines for the treatment of important eye diseases.

Geographical spread of employment 2012

The Company's success to-date has been due to its ability to react quickly to both the challenges and opportunities affecting its business. All staff members are driven by the feeling that their work is connected to the corporate strategy and that their contribution can make a real impact. As a result, the Company ensures that all employees have the resources and support they require to remain motivated and succeed in their roles.

Most employees hold a Masters or PhD degree, and the ThromboGenics team is international. ThromboGenics values diversity and is committed to providing equal employment opportunities for all its employees.

Members of the ThromboGenics US team



Members of the R&D team

ThromboGenics has grown considerably since it relocated from university labs to the BioIncubator Park in Leuven, Belgium in 2009. The Company's total global headcount grew to 134 (181 including third party partners) by the end of 2012. The majority is based in ThromboGenics' headquarters in Leuven, Belgium, although the number of staff based in other offices rose in 2012, with 84 (incl. third party partners) employees in the US, six in Ireland, five in the UK, two in France and one in Germany.

ThromboGenics intends to continue strengthening the team with the right people with the right attitude and mix of skills, as this is fundamental to the Company achieving its strategic goals.

Board members

Board of Directors

There are two executive members of ThromboGenics' board of directors: Patrik De Haes, Chief Executive Officer, and Chris Buyse, Chief Financial Officer.

The non-executive board members, not employed by the Company in a full time capacity, consist of Désiré Collen, Chairman and Founder of ThromboGenics; Staf van Reet, Chairman of ActoGeniX, a clinical stage pharmaceutical company, and Managing Director of Viziphar Biosciences BVBA; Luc Philips (Lugost BVBA), ex-CFO at KBC Bank; Thomas Clay, member of East Hill Advisors, a US-based venture capital firm specializing in the lifescience sector and Vice President of East Hill Management Company, LLC, Jean-Luc Dehaene, former prime minister of Belgium and Vice Chairman of the European Convention; and Patricia Ceysens (Innov'Activ BVBA), former minister of Economic Affairs of the Flemish Government, Member of the Flemish Parliament and president of the Commission Economy Innovation, Science Policy, Employment and Social Economy. Patricia joined the Board on May 2, 2012.

From left to right: Chris Buyse, Luc Philips, Jean-Luc Dehaene, Thomas Clay, Patricia Ceysens, Patrik De Haes, Désiré Collen, Staf Van Reet

From left to right: Chris Buyse, Lene Rose Arfelt, Wouter Piepers, Ram Palanki, Ove Pedersen, Laurence Raemdonck, David Pearson, Patrik De Haes, Koen Kas, Andy De Deene, Chris Jaeggi, Keith Steward, Paul De Nijs, Aniz Girach, not shown: Rosemarie Corrigan, Claude Sander

Board Committees

The Board of Directors has established an Audit Committee and a combined Nomination and Remuneration Committee. The Board of Directors appoints the members and the chairman of each committee, which consists of at least 3 members. Since 2012 the composition of the committees has been as follows:

Audit Committee

Luc Philips (Lugost BVBA), chairman; Staf Van Reet (Viziphar Biosciences BVBA); Thomas Clay (Vice-President of East Hill Management Company, LLC) and Jean-Luc Dehaene.

Nomination and Remuneration Committee

Staf Van Reet (Viziphar Biosciences BVBA), chairman; Jean-Luc Dehaene and Patricia Ceysens (Innov'Activ BVBA).

Extended executive team

ThromboGenics' extended executive team is composed of people with extensive backgrounds in corporate leadership, research, clinical development, commercialization and finance. The team consists of Patrik De Haes, Chief Executive Officer; Chris Buyse, Chief Financial Officer; Andy De Deene, Head of Program Management; Laurence Raemdonck, Head of Human Resources; David Pearson, Head of Country Operations US; Christian Jaeggi, Head of Country Operations EU/ROW; Ram Palanki, Head of Sales & Marketing; Aniz Girach, Head of Clinical Ophthalmology; Koen Kas, Chief Scientific Officer; Paul De Nijs, Head of Market Access; Lene Rose Arfelt, Head of Regulatory Affairs; Keith Steward, Head of Medical Affairs; Ove Pedersen, Head of Product Supply; Rosemarie Corrigan, Head of Quality Assurance; Wouter Piepers, Head of Corporate Communications and Claude Sander, General Counsel & Corporate Compliance Officer.

The extended executive team is responsible for the vision and strategy of the Company, and meets on a regular basis to plan and oversee the implementation of ThromboGenics' plans and policies.

Shareholders information

NYSE Euronext Brussels

Listing

ThromboGenics shares are listed on the Eurolist by NYSE Euronext Brussels under the symbol THR. Since 2009, ThromboGenics has been included in the NEXT 150 Index, which comprises mid- to large-capitalization stocks on the Euronext exchange. As of December 24, 2012 ThromboGenics' shares became part of the STOXX Europe 600 Index. This index represents large-, mid- and small-capitalization companies across 18 countries in Europe.

Investor relations

Our investor relations policies include:

- providing reliable, accurate, and valuable information in a timely manner to help shareholders make informed decisions
- providing full transparency
- operating within the Company's policies and adhering to the relevant security laws and regulations
- having a pro-active on-going dialogue with the investment community
- providing access to the senior management team on a consistent basis



Stock chart information

Last	Open	High	Low	Volume	Close D-1	Change vs Close D-1
44.32	44.00	46.20	43.57	404,291	42.71	3.31 %

Last: 31/12/2012 16:35:00

Best 5 bid & ask orders

Ordervolume	Volume	Bid	Ask	Volume	Ordervolume
3	406	44.30	44.32	454	1
1	400	44.28	44.33	1,371	1
1	52	44.27	44.34	400	1
4	2,381	44.25	44.38	1,230	5
2	1,476	44.23	44.39	581	1

High/low

Period	High	Date	Low	Date
Week	43.94	02/01/2013	41.10	27/12/2012
Month	43.94	02/01/2013	36.85	03/12/2012
Year	43.94	02/01/2013	17.10	05/06/2012

Analyst coverage

Bank	Analyst	Website
Inside Beleggen	Danny Reweghs	www.insidebeleggen.be
Jefferies International Ltd	Peter Welford	www.jefferies.com
KBC Securities	Jan De Kerpel	www.kbsecurities.com
Kempen	Mark Pospisilik / Sachin Soni	www.kempen.com
Petercam	Roderick Verhelst	www.petercam.com

INFORMATION FOR SHAREHOLDERS / GLOSSARY

Shareholding structure

As of December 31, 2012, ThromboGenics has a total number of 35,860,224 outstanding shares and a total number of 1,040,625 outstanding warrants. The free float amounts to 73.1%. The shareholding structure can be summarized as follows:



Financial calendar

Thursday, March 14, 2013
Full Year Results 2012

Tuesday, May 7, 2013
General Shareholders Meeting 2013

Thursday, May 16, 2013
Business Update Q1

Thursday, August 27, 2013
Half Year Results 2013

Thursday, November 7, 2013
Business Update Q3

Paying agent services

KBC Bank acts as the Company's paying agent. The paying agent will not charge shareholders with respect to payments of dividends, the exercise of subscription rights and other events concerning ThromboGenics' shares.

Registered office

ThromboGenics NV
Gaston Geenslaan 1
B-3001 Leuven
Belgium
T +32 (16) 75 13 10
F +32 (16) 75 13 11
info@thrombogenics.com

Investor relations contact

ThromboGenics NV
Gaston Geenslaan 1
B-3001 Leuven
Belgium

chris.buyse@thrombogenics.com
wouter.piepers@thrombogenics.com

www.thrombogenics.com

Glossary

AMD	Age-related Macular Degeneration
Anti-PIGF	Anti-Placental Growth Factor
BLA	Biological License Application
DMA	Diabetic Macular Edema
DR	Diabetic Retinopathy
EMA	European Medicines Agency
FDA	Food and Drug Administration
FTMH	Full-Thickness Macular Hole
ICD-9-CM	International Classification of Diseases, ninth revision, Clinical Modification
MAA	Marketing Authorization Application
Metamorphopsia	Distorted vision
Ocriplasmin	Formerly known as microplasmin, commercialized as JETREA®
PVD	Posterior Vitreous Detachment
R&D	Research & Development
Symptomatic VMA	Symptomatic Vitreomacular Adhesion
VA	Visual Acuity
VMA	Vitreomacular Adhesion
CHMP	Committee for Medicinal Products for Human Use
VMT	Vitreomacular Traction